These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 34590755)

  • 21. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection.
    Kim DY; Paik YH; Ahn SH; Youn YJ; Choi JW; Kim JK; Lee KS; Chon CY; Han KH
    Oncology; 2007; 72 Suppl 1():52-7. PubMed ID: 18087182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy.
    Loglio A; Iavarone M; Facchetti F; Di Paolo D; Perbellini R; Lunghi G; Ceriotti F; Galli C; Sandri MT; Viganò M; Sangiovanni A; Colombo M; Lampertico P
    Liver Int; 2020 Aug; 40(8):1987-1996. PubMed ID: 32301212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of prothrombin induced by vitamin K absence, macrophage migration inhibitory factor and Golgi protein-73 versus alpha fetoprotein for hepatocellular carcinoma diagnosis and surveillance.
    Ismail MM; Morsi HK; Abdulateef NA; Noaman MK; Abou El-Ella GA
    Scand J Clin Lab Invest; 2017 May; 77(3):175-183. PubMed ID: 28276727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
    Xu F; Zhang L; He W; Song D; Ji X; Shao J
    Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins glypican-3, Alpha feto protein and carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients.
    Abd El Gawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
    J Egypt Natl Canc Inst; 2014 Jun; 26(2):79-85. PubMed ID: 24841158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.
    Gad A; Tanaka E; Matsumoto A; Wahab MA; Serwah Ael-H; Attia F; Ali K; Hassouba H; el-Deeb Ael-R; Ichijyo T; Umemura T; Muto H; Yoshizawa K; Kiyosawa K
    World J Gastroenterol; 2005 Nov; 11(42):6607-12. PubMed ID: 16425352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].
    Zhang JW; Guan LY; E CY; Yang JH; Xuan W; Meng ZH; Li W
    Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):776-781. PubMed ID: 32993265
    [No Abstract]   [Full Text] [Related]  

  • 28. Prothrombin induced by vitamin K absence or antagonist-II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C-related cirrhosis treated with direct-acting antiviral agents.
    Degasperi E; Perbellini R; D'Ambrosio R; Uceda Renteria SC; Ceriotti F; Perego A; Orsini C; Borghi M; Iavarone M; Bruccoleri M; Rimondi A; De Silvestri A; Sangiovanni A; Lampertico P
    Aliment Pharmacol Ther; 2022 Feb; 55(3):350-359. PubMed ID: 34738664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.
    Su TH; Peng CY; Chang SH; Tseng TC; Liu CJ; Chen CL; Liu CH; Yang HC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Mar; 121(3):703-711. PubMed ID: 34452785
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
    Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
    J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
    Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
    Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of ED036 kit for measuring serum PIVKA-II levels in small hepatocellular carcinoma.
    Kuromatsu R; Tanaka M; Shimauchi Y; Shimada M; Tanikawa K; Watanabe K; Yokoo T
    J Gastroenterol; 1997 Aug; 32(4):507-12. PubMed ID: 9250899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M; Gama H; Chida N; Ueno Y; Shinzawa H; Takagi T; Toyota T; Takahashi T; Kasukawa R
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Morota K; Nakagawa M; Sekiya R; Hemken PM; Sokoll LJ; Elliott D; Chan DW; Dowell BL
    Clin Chem Lab Med; 2011 Apr; 49(4):711-8. PubMed ID: 21231906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
    Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PIVKA-II is a useful tool for diagnostic characterization of ultrasound-detected liver nodules in cirrhotic patients.
    Saitta C; Raffa G; Alibrandi A; Brancatelli S; Lombardo D; Tripodi G; Raimondo G; Pollicino T
    Medicine (Baltimore); 2017 Jun; 96(26):e7266. PubMed ID: 28658121
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study.
    Abdel-Razik A; Elhelaly R; Elzehery R; El-Diasty A; Abed S; Elhammady D; Tawfik A
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):599-605. PubMed ID: 26741637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
    Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
    Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma.
    Qi F; Zhou A; Yan L; Yuan X; Wang D; Chang R; Zhang Y; Shi F; Han X; Hou J; Wei L; Zhang X
    J Clin Lab Anal; 2020 May; 34(5):e23158. PubMed ID: 31821607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic accuracy of serum protein induced by vitamin K absence (PIVKA-II), serum a-fetoprotein and their combination for hepatocellular carcinoma among Caucasian cirrhotic patients with diagnostic or non-diagnostic serum a-fetoprotein levels.
    Syriha A; Pantzios S; Mandilara D; Galanis P; Stathopoulou I; Barla G; Elefsiniotis I
    Cancer Med; 2024 Feb; 13(3):e6825. PubMed ID: 38361401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.